STOCK TITAN
  1. Home
  2. Sec-filings
  3. CAI
  4. [Form 4] Caris Life Sciences, Inc. Insider Trading Activity

Caris Life Sciences (CAI) director receives 13,192-share restricted stock award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Caris Life Sciences, Inc. reported that director David Paul Fredrickson received an equity compensation award. He acquired 13,192 shares of Common Stock on August 14, 2026, at a stated price of $0.00 per share, representing an award of restricted stock units that vest under the applicable grant agreement. Following this award, his directly held Common Stock position increased to 31,813 shares.

Positive

  • None.

Negative

  • None.
Insider Fredrickson David Paul
Role Director
Type Security Shares Price Value
Grant/Award Common Stock F1 13,192 $0.00 $0.00
Holdings After Transaction: Common Stock — 31,813 shares (Direct)
Footnotes (1)
  1. F1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Shares awarded 13,192 shares of Common Stock Grant/award acquisition on August 14, 2026
Per-share price $0.00 per share Stated transaction price for RSU award
Shares owned after 31,813 shares Total Common Stock directly held by David Paul Fredrickson after the award
restricted stock units financial
"Represents an award of restricted stock units which vest in accordance"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
grant, award, or other acquisition financial
"transaction code description is Grant, award, or other acquisition"
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

What insider transaction did Caris Life Sciences (CAI) report for David Paul Fredrickson?
Caris Life Sciences reported that director David Paul Fredrickson received an award of 13,192 shares of Common Stock on August 14, 2026. The award consists of restricted stock units that vest according to the related grant agreement.

How many Caris Life Sciences (CAI) shares does David Paul Fredrickson hold after this Form 4 transaction?
After the reported award, David Paul Fredrickson holds 31,813 shares of Caris Life Sciences Common Stock directly. This figure reflects his ownership following the grant of 13,192 restricted stock units on August 14, 2026.

Was the Caris Life Sciences (CAI) Form 4 transaction a purchase or an award?
The Form 4 reports an award of restricted stock units, not an open-market purchase. Code “A” indicates a grant or award acquisition of 13,192 shares at a stated per-share price of $0.00, subject to vesting terms.

What type of security did Caris Life Sciences (CAI) grant to David Paul Fredrickson?
The company granted Common Stock in the form of restricted stock units. The footnote explains that the 13,192 reported shares represent an award of restricted stock units that vest under the applicable grant agreement.

Does the Caris Life Sciences (CAI) Form 4 indicate a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 checkbox is not affirmed for this transaction. The structured data shows the 10b5-1 affirmation field as false, and the accompanying footnote does not reference any trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fredrickson David Paul
(Last)(First)(Middle)
C/O CARIS LIFE SCIENCES, INC.
750 W. JOHN CARPENTER FREEWAY, SUITE 800
(Street)
IRVING TEXAS 75039
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Caris Life Sciences, Inc. [ CAI ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/14/2026A13,192(1)A$031,813D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
Remarks:
/s/ J. Russel Denton, Attorney-in-Fact08/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR